https://pmc.ncbi.nlm.nih.gov/articles/PMC12673297/
A real-world retrospective analysis to evaluate the efficacy and safety of surufatinib in the...
Surufatinib, an oral vascular immune kinase inhibitor targeting angiogenesis and immune escape, is approved in China for the treatment of unresectable locally...
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1361628/full
Frontiers | Case report: Remarkable response to later-line surufatinib in an adult patient with...
Pancreatoblastoma (PB), a neoplasm derived from pancreatic follicular cells, primarily affects the pediatric population. Although infrequent in adults, it is...
https://www.biospace.com/chi-med-and-beigene-enter-into-clinical-collaboration-to-evaluate-combinations-of-surufatinib-and-fruquintinib-with-tislelizumab
Chi-Med and BeiGene Enter into Clinical Collaboration to Evaluate Combinations of Surufatinib and...
May 26, 2020 - Hutchison China MediTech Limited and BeiGene, Ltd. announced that they have entered into a clinical collaboration agreement to evaluate the safety,...
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1546217/full
Frontiers | Surufatinib related nephrotic syndrome in a pancreatic neuroendocrine tumor: a case...
Pancreatic neuroendocrine tumors (pNETs) are rare, heterogenous neoplasms originating from pancreatic neuroendocrine cells, which regulate hormone secretion ...
nephrotic syndromein aneuroendocrine tumorfrontierssurufatinib